The Swiss Market Index (SMI) recovered from initial losses shortly after the opening bell, finding support primarily from heavyweight pharmaceutical stocks Roche and Novartis.
Broader market movements saw mixed performances across various Swiss equities, with several smaller and mid-cap companies reacting to new analyst ratings and price targets. Trading conditions remained relatively range-bound as the benchmark index navigated the session without major macroeconomic catalysts.
